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Abstract
The rational design of anti-cancer agents includes a new approach based on ruthenium complexes 
that can act as nitric oxide (NO) donor agents against specific cellular targets. One of the most 
studied classes of those compounds is based on bis(bipyridine) ruthenium fragment and its 
derivative species. In this work, we present the chemical and cytotoxicity properties against the 
liver hepatocellular carcinoma cell line HepG2 of cis-[RuII(NO+)Cl(dcbpy)2]2− conjugated to a 
polyclonal antibody IgG (anti-VDAC) recognizing a cell surface marker. UV–visible bands of the 
ruthenium complex were assigned with the aid of density functional theory, which also allowed 
estimation of the structures that explain the biological effects of the ruthenium complex–IgG 
conjugate. The interaction of cis-[RuII(NO+)Cl(dcbpy)2]3− with mitochondria was evaluated due 
to the potential of these organelles as anti-cancer targets, and considering they interact with the 
anti-VDAC antibody. The cytotoxicity of cis-[RuII(NO+)Cl(dcbpy)2]3−-anti-VDAC antibody was 
up to 80% greater in comparison to the free cis-[RuII(NO+)Cl(dcbpy)2]3− complex. We suggest 
that this effect is due to site-specific interaction of the complex followed by NO release.
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Introduction
In the last decade, there has been growing interest in the physiology of nitric oxide (NO) 
which has led to the development of a variety of new NO donors [1–7]. Metal-based 
compounds are one of the most promising classes of NO donor agents. Among these 
compounds, nitrosyl ruthenium complexes are the most studied and best understood species 
[4, 5, 8–21].
In general, these complexes have the structure {Ru–NO}3+, and they can act as NO delivery 
agents via (a) a reduction process [12, 15–17], (b) via direct light irradiation on the metal–
ligand charge transfer band dπ(RuII)–π*(NO+) [16, 17], or (c) by photoinduced electron 
transfer [20, 21]. Depending on the pH, {Ru–NO}3+ can be fully converted to {Ru–NO2}+, 
which could act as an NO delivery agent either by photolysis or by an oxygen transfer 
reaction, as described in the literature [16, 22]. The dπ(RuII)–π*(NO+) backbonding 
strongly influences the formation of the nitro compound [22].
For example, in the case of the complex cis-[Ru(NO2) (bpy)2L]n+/0 (L = Cl−, pyridine, 
isonicotinamide, 4-picoline, or 4-acetylpyridine), and where bpy is bipyridine (a strong π-
acceptor ligand), cis-[RuII(NO+)(bpy)2L]n+1 is formed when the complex is dissolved in 
aqueous solution at pH ≤ 4.0 [5]. This may pave the way for the application of this kind of 
system in bioassays, which are usually conducted in physiological pH. Regarding in vitro 
and in vivo assays, NO delivery agents based on ruthenium complexes have been used for a 
number of biological purposes [4] including experiments on vasorelaxation [22], Chagas 
disease [23–25], and cytotoxicity [12–15]. Maybe the most appealing feature is the 
possibility to control the amount of NO release based on the uptake of ruthenium species. 
For example, in cancer cells, NO has been suggested to modulate several different events 
[26, 27]. It seems to show dual functionality: NO can be anti- or pro-tumorigenic depending 
on its local concentration [26]. NO levels between 50 and 100 nM activate signal 
transduction pathways that elicit tumorigenic effects; above this level, NO exerts antitumoral 
functions [26]. The key to maximize the efficacy and/or reduce the side effects associated 
with NO, is better targeted delivery of these agents to tumor sites. Several strategies have 
been used in this way mainly focus in drug delivery system [28–34]. Although targeting NO 
delivery agents can promote an increase in cellular uptake, it may reduce overall cytotoxicity 
since certain threshold levels of NO over large areas may be required for activation of 
signaling pathways. Effective targeted NO delivery agents based on ruthenium complexes 
may improve local NO concentration, which could increase the cytotoxic effect of the nitric 
oxide derivative ruthenium complex. Compounds containing ruthenium(II) and some 
unsaturated ligands “L” show good stability mainly due to existing backbonding dπ(RuII)–
π*(L), and have been used as models in kinetic and photochemical studies [35, 36]. One 
class of compounds, for example, [RuII(bpy)2L(NO+)]n+ has been studied due to its thermal 
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stability, and also its ability to release NO under external stimulation [4, 9, 10, 13, 14, 37–
40]. This suggests these compounds might find applications as NO delivery agents and 
possible anti-cancer agents. One possible target within cancer cells is mitochondria. In 
addition to providing cellular energy, these organelles play an important role in cell 
signaling events, including those involving cell death [41]. The voltage-dependent anion 
channel (VDAC) is a protein in the mitochondrial outer membrane, controlling cross-talk 
between mitochondria and the remainder of cell. VDAC plays a central role in mitochondria-
mediated apoptosis by means of reactive oxygen species (ROS) generation, and it should be 
noted that NO can increase ROS levels [41]. Therefore, VDAC is a potential target for NO 
donor agents based on ruthenium complexes.
To achieve this goal, one approach to improve the molecular specificity of the ruthenium 
complex is by attaching it to a ligand that recognizes a surface marker that is preferentially 
expressed in cancer cells. Such strategy has been used for some ruthenium complexes [42, 
43]. Hence, this work aimed to evaluate the cytotoxic effect of polyclonal antibody IgG, 
anti-VDAC conjugated to the nitrosyl ruthenium complex cis-[Ru(NO)Cl(dcbpy)2]3− where 
dcbpy is 2,2′-bipyridine-4,4′-dicarboxylic acid as a NO delivery agent against the 
hepatocellular carcinoma cell line (HepG2).
Materials and methods
Chemical and reagents
RuCl3·nH2O, sodium nitrite, triethanolamine, N,N′-dicyclohexylcarbodiimide (DCC), and 
N-hydroxysuccinimide (NHS) were purchased from Sigma-Aldrich Chemicals (Brazil) as 
high purity reagents. VDAC 1/2/3, FL-238, and rabbit polyclonal IgG (200 μg mL−1) were 
acquired from Santa Cruz Biotechnology (Santa Cruz, USA). Doubly distilled water was 
used in all experiments. Nitric oxide was prepared by the reaction of nitric oxide with copper 
turnings and was purified according to the literature method [37].
Apparatus
The ultraviolet–visible (UV–Vis) spectra were recorded on an Agilent 8453 
spectrophotometer; the samples were placed in a quartz cell with an optical path length of 1 
cm. The infrared spectra were acquired on a Prestige 21 Schimadzu FTIR spectrometer; the 
samples were pressed into KBr pellets.
The pH was measured with a DM 20 pH meter (Digimed). The photochemical experiments 
were carried out in aqueous solution containing the ruthenium complex at 1.0 × 10−4 M. A 
447-nm Diode Laser Colibri (Quantum Tec®) was employed. The electrochemical studies 
were performed in aqueous solution using an AUTOLAB PGSTAT 30 potentiostat/
galvanostat. A conventional three-electrode cell arrangement consisting of a glassy carbon 
disk working electrode, a platinum wire auxiliary electrode, and an Ag/AgCl reference 
electrode was employed. The supporting electrolyte was KCl at 0.1 mol L−1.
NO was measured on a Dual Channel Nitric Oxide Measuring system inNO-T equipped 
with a selective amperometric sensor amiNO-600 from Innovative Instruments, Inc. Mass 
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spectrometry was accomplished on an ULTROTOFQESI-TOF Mass Spectrometer (Bruker 
Daltonics, Billerica, USA) operating in the positive mode.
Computational methodology
Density functional theory (DFT) computations were employed to fully optimize the ground 
state geometries of all the species described in this work. The calculations were done with 
Gaussian 09 using Becke’s three-parameter hybrid functional with the correlation functional 
of Lee, Yang and Parr formalized as the B3LYP hybrid functional [44–47] and the effective 
core potential basis set LanL2DZ [48–51], which proved to be suitable for geometry 
predictions in coordination compounds containing metals of the second row of the transition 
elements in the periodic table. Different degrees of protonation of the carboxylate groups in 
the dcbpy ligand were explored. The non-equivalency of the –CO2− groups of the molecule 
renders four different possibilities for monoprotonation and six possible combinations for 
diprotonation. In addition, the carboxylato groups can be engaged in solute–solvent 
hydrogen-bonding specific interactions, which have to be taken into account to avoid 
artifacts in the computations arising from the excess of negative charge on the CO2− 
substituents. For this purpose, four explicit water molecules were incorporated in the 
geometry optimizations and all subsequent computations. All the different cases of mono- 
and diprotonated structures plus the fully deprotonated molecule were fully optimized in 
vacuo. Tight SCF convergence criteria and default setting were used along the geometry 
optimizations. In all cases, vibrational analyses prove that the stationary points reached 
along the optimizations correspond to local minima in the potential energy surface. The 
computations suggest that whereas the monoprotonated stage is dominated by one single 
species, several isomers might contribute in significant proportions to the diprotonated 
species. The analysis of the electronic structure was complemented with (TD)DFT 
computations including at least 90 states of the same multiplicity than the ground state. The 
spectra were computed at the gas phase geometry. Apart from the explicit water molecules 
solvation effects in aqueous solution were incorporated in the computations employing the 
PCM approximation, as implemented in Gaussian 09.
Synthesis of cis-[Ru(NO)Cl(dcbpy-H)2]
The complex cis-[Ru(NO)Cl(dcbpy-H)2] (Ru-DCBPY) was synthesized according to a 
previously similar published procedure [21]. The complex cis-[RuCl2(dcbpy-H2)2] was the 
starting material; it was prepared in the same way as cis-[RuCl2(bpy)2]·2H2O, described in 
[38]. Briefly, cis-[RuCl2(dcbpy-H2)2]·2H2O (0.100 g, 0.14 mmol) was dissolved in 25 mL of 
milli-Q H2O and degassed with argon for 30 min. Gaseous NO was then generated by 
reaction between nitric acid solution (50% V/V) and metallic copper. The produced gaseous 
mixture was passed through a concentrated NaOH solution to eliminate NO2 traces. The 
nitric oxide was then bubbled through the cis-[RuCl2(dcbpy-H2)2]·2H2O complex solution 
for 40 min to give a reddish-brown solution. This procedure was repeated three times for 24 
h under constant stirring. The resulting brown precipitate was collected by filtration, washed 
with 30 mL of diethyl ether, and stored under vacuum in the dark. Yield: 59% (Anal. calc. 
for C24H22N5O13ClRu: C, 39.76; H, 3.06; N, 9.66. Found: C, 39.31; H, 2.96; N, 9.51%). 
m/z = 652.95 ({[Ru(NO)Cl(dcbpy-H)2]}+).
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Isolation of rat liver mitochondria
Mitochondria were isolated by standard differential centrifugation [52]. Male Wistar rats 
weighing approximately 200 g were killed by decapitation, according to research protocols 
approved by CEUA-USP, Rib. Preto. Livers (10–15 g) were immediately removed, sliced in 
medium (50 mL) consisting of 250 mM sucrose, 1 mM ethyleneglycolbis(β-aminoethyl)-
N,N,N′,N′-tetraacetic acid (EGTA), and 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES)–KOH, pH 7.2, and homogenized three times for 15 
s, at 1-min intervals, with a Potter–Elvehjem homogenizer. Homogenate was centrifuged 
(580g, 5 min), and the resulting supernatant was centrifuged further (10,300g, 10 min). 
Pellets were then suspended in medium (10 mL) consisting of 250 mmol L−1 sucrose, 0.3 
mM EGTA, and 10 mM HEPES–KOH, pH 7.2, and centrifuged (3400g, 15 min). The final 
mitochondrial pellet was suspended in medium (1 mL) consisting of 250 mM sucrose and 10 
mM HEPES–KOH, pH 7.2, and used within 3 h. Mitochondrial protein content was 
determined by the Biuret reaction. For the assays, mitochondria (0.5 or 1 mg protein mL−1) 
were energized with 5 mM potassium succinate (plus 2.5 μM rotenone) in a standard 
medium consisting of 125 mM sucrose, 65 mM KCl, and 10 mM HEPES–KOH, pH 7.4, at 
30 °C.
Direct detection of NO release from complex (Ru-DCBPY)
NO release from complex (Ru-DCBPY) (100 μM) after incubation with succinate-energized 
mitochondria (1 mg protein mL−1) in standard medium was assessed with a Selective Sensor 
Electrode (AmiNO 700) in the dark.
Mitochondrial assays
Mitochondrial oxygen consumption was monitored in the standard medium, in an oxygraph 
equipped with a Clark-type oxygen electrode (Hansatech instruments, oxytherm electrode 
unit, UK). Mitochondrial membrane potential was estimated spectrofluorimetrically; 10 μM 
of cationic dye safranine O was used as probe and fluorescence was measured at 495/586 
nm excitation/emission wavelength pair [53]. ROS/RNS levels were evaluated by monitoring 
oxidation of dichlorodihydrofluorescein diacetate (H2DCFDA) (Molecular Probes, Eugene) 
at the 503/528 nm excitation/emission wavelength pair [54]. The fluorimetric experiments 
were accomplished on a Hitachi Model F-4500 spectrofluorimeter (Tokyo, Japan). 
Mitochondrial swelling was estimated from the decrease in the apparent absorbance at 540 
nm [55].
Synthesis of cis-[RuCl(dcbpy)2(NO2)]4−-anti-VDAC
The porin antibody anti-VDAC was bound to the (Ru-DCBPY) forming cis-[RuCl 
(dcbpy)2(NO2)]4−-anti-VDAC via amide bond formation using a procedure similar to the 
procedure described by Terpetsching et al. [56]. In this protocol, DCC (0.230 g, 1.11 mM) 
and NHS (0.119 g, 1.030 mM) were dissolved in dimethylformamide (3.0 mL), under 
stirring, and cooled in an ice bath. Next, (Ru-DCBPY) (0.200 g, 2.53 mM) was added, and 
the mixture was stirred for 2 h. The precipitate was removed by filtration through a syringe 
filter (Millipore-Millex 0.22 μm). The filtrate (500 μL) containing the active Ru complex 
was added to an IgG solution in 0.2 M carbonate buffer pH 8.3 (1.0 mL, 1% IgG) and stirred 
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for 12 h. Purification of the labeled protein was performed by gel filtration chromatography 
on Sephadex G-25 coupled to a peristaltic pump (GILSON, miniplus 3) at 1 mL min−1 flow; 
0.1 M phosphate buffer pH 7.2 was used. The fractions were collected in a Fraction 
Collector LKB, BROMA.
Antibody detection (western blotting) and (UV–Vis) assessment of fractions
IgG (anti-VDAC) was determined in (aliquot) fractions by western blotting. The 
mitochondria harvested from aliquots obtained from the Sephadex column were re-
suspended in CelLytic™M (Sigma, Brazil) lysis buffer for 2 min, on ice, and centrifuged at 
10,000g for 5 min. The resulting supernatants were subjected to 12% SDS-PAGE, 
transferred to a nitrocellulose membrane, and probed with antibodies against cytochrome c 
(BD Pharmigen, purified mouse anticytochrome c) followed by horseradish peroxidase-
coupled detection.
HepG2 cell culture
The HepG2 cells were obtained from the American Type Culture Collection. The cell line 
was cultured in Dulbecco’s medium supplemented with 10% fetal bovine fetal serum, 100 
IU mL−1 penicillin G, 100 mg mL−1 streptomycin, and 1 μg mL−1 amphotericin. The cells 
were plated in 6, 12, 24 and 96-well plates and cultured until 75–90% confluence was 
achieved (depending on the assay) in a humidified incubator at 37.0 °C with 5.0% CO2.
MTT cell viability assay
The viability of the HepG2 cells was assessed by means of the [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide] (MTT) colorimetric assay. The cells were plated on 
96-well microtiter cell culture plates at 2 × 104 cells/well for 24 h. After the indicated 
treatment, the cells were incubated at 37.0 °C for 3 h in a culture medium containing 10 mol 
L−1 MTT in phosphate-buffered saline (PBS). The blue MTT formazan precipitate was then 
dissolved in 50 L of DMSO, and the absorbance was measured at 570 nm with a multi-well 
plate reader [57]. The cell viability was expressed as the percentage of the absorption values 
in the treated cells relative to the non-treated (control) cells. The data are presented as the 
means ± the standard error of three independent experiments.
Statistical analysis
Statistical analysis was performed by two-way ANOVA. Equality of variance was assumed 
with Bonferroni’s post hoc test for pairwise comparisons. Results with P < 0.05 were 
considered statistically significant.
Results and discussion
NO bubbling through an aqueous cis-[RuCl2(dcbpy-H2)2] solution afforded the nitrosyl 
ruthenium complex (Ru-DCBPY) in high yield. Elemental analyses of complex (Ru-
DCBPY) as well as mass spectrum analysis (Supplementary material: Figure 1) agreed with 
the proposed molecular formula. Complex (Ru-DCBPY) displayed electronic absorption 
spectrum with poor defined bands at 323 nm (log ε = 3.97) and 305 nm (log ε = 4.13), 
which was assigned based on theoretical calculations. Figure 1 provides a schematic 
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representation of the (Ru-DCBPY) complex, with the carboxylato groups labeled to assist in 
the discussion that follows. Table 1 compiles the most relevant DFT-computed structural 
parameters (Ru–N and N–O distances, Ru–N–O angle and IR frequencies) for the different 
cis-[RuII(NO+) Cl(dcbpy-Hx)2]n (n vary of 2+ to −2) species explored in this work.
The metric parameters are within the expectations for this kind of compounds, with slight 
differences depending on the presence or absence of explicit water molecules along the 
optimization procedure. In all cases, the N–O bond length at ca. 1.19 Å and the almost linear 
Ru–N–O moiety is consistent with a predominant RuII–NO+ character. The computations 
predict NO stretching frequencies (νNO) be insensitive to the protonation degree of the 
complex. Although the trans NO ligand has offered effect on the nitrosyl stretching 
frequency [58, 59], it seems to be not the case for nitrosyl bipyridine ruthenium complexes, 
in which a net effect for the σ-donor and π-acceptor character of different forms of 
carboxybipyridine ligand does not show significant change on the νNO stretching frequency. 
Bipyridine nitrosyl ruthenium(II) complexes present νNO stretching bands in the 1800–2000 
cm−1. The peak intensity varies from medium to strong [4, 5, 10, 12–16, 20, 23, 37–40, 58–
60]. In the FTIR spectrum of (Ru-DCBPY) complex, νNO was found in 1945 cm−1 
indicating that the complex is of {RuII-NO+}6 type. In addition, the spectrum exhibits peaks 
at 1610, 1560 and 1460 cm−1, which is characteristic of the pyridine rings. The carboxylate 
group is evidenced by a peak at 1690 cm−1. The calculated νNO stretching frequencies for 
(Ru-DCBPY) in this work were 1800 cm−1, which are lower than the experimental ones. It 
is in part due to a tendency of DFT methods with standard functionals to provide too 
delocalized molecular and electronic structures due to inherent self-interaction errors [61–
63]. However, the inclusion of explicit water molecules at hydrogen-bonding distance of the 
carboxylato groups brings the νNO values closer to the experimental ones. In the absence of 
these specific interactions, the high charge located on the –CO2− groups leads to several 
anomalies, not only in the stretching frequencies but also in the electronic structure picture 
and the predicted electronic spectroscopy. Even when isolated molecules have been included 
in the table for completeness, the following discussion will involve only hydrogen-bonded 
complexes.
There is no easy way to obtain by DFT reliable acidity constant values, which could assist in 
the determination of the degree of protonation in solution. The literature related to other 
species holding the {Ru(dcbpy)2}2+ core suggests that, at the pH employed in our 
experiments, the nitrosyl species is probably best described as holding an average of two 
protonated carboxylato sites. Simple enthalpic arguments allow establishing that three out of 
the six possible diprotonated species present in solution (labeled 6–11 in Table 1) should 
predominate in acidic aqueous solution, with still non-negligible amounts of the remaining 
ones. The electronic structure and the (TD)DFT predicted spectra for all these species are in 
fact very similar, because the Ru–NO interaction dominates the orbital ordering. Figure 2 
displays a MO diagram highlighting some relevant orbitals computed for isomer 6, expected 
to be the most abundant in solution.
The antibonding LUMO and LUMO + 1 orbitals have 22 and 25% contribution of metal-
centered atomic orbitals, reflecting extensive mixing between the Ru dπ and the NO π* 
orbitals. This composition is comparable to other {RuNO}6 species and is consistent with a 
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well-preserved nitrosonium character of the coordinated NO fragment. The high covalency 
of the Ru–NO bond results in a noticeable stabilization of the dπ orbitals, which leads to a 
HOMO that is mostly centered on the non-protonated carboxylato groups of the dcbp ligand. 
The occupied MOs immediately below the HOMO are also dcbpy, dcpyH2 or Cl− centered 
and show little contribution from the Ru fragment. The HOMO-8 is the first MO with 
measurable dπ Ru-centered contribution, and it is necessary to go as deep as HOMO-10 and 
HOMO-18 to find the bonding MOs that result from the interaction between the dπ set and 
the nitrosyl ligand. This electronic picture results in an electronic spectrum, which is shifted 
to the high energy end of the visible region of the spectrum. In aqueous acidic medium, the 
Ru-DCBPY was found to be light yellow in color exhibiting band at 305 nm. The spectrum 
feature was similar to the data reported in the literature for nitrosyl ruthenium bipyridine [5, 
14, 17, 21, 22, 37]. Figure 3 compares the experimental and computed electronic spectra.
The individual six possible diprotonated species spectra show very subtle variations. 
Nevertheless, the differences in the absorption maxima for the six cases are within the error 
for the computational methodology, allowing to focus the analysis on one particular example 
without loss of generality. For the species number 6 (TD)DFT predicts the most intense 
absorption in the 250–800 nm to be centered at 315 nm. This transition, which is mostly a 
ligand-to-ligand charge transfer transition between dcbpyH2 and NO+ centered MO’s, 
accounts for the experimental absorption maximum at 305 nm. The shoulder at lower 
energies originates in a series of closely spaced low intensity absorptions of similar origin 
involving any of the three dcbpy, dcpyH2 or Cl− co-ligands. These transitions overlap with 
the usual π–π* absorptions due to the bipyridinic moieties. Finally, the experimental weak 
absorption band in the 450–500 nm region seems to involve transitions between orbitals in 
the range HOMO-7 to HOMO-14 and the NO-centered LUMO and LUMO + 1 orbitals and 
have mixed ligand to ligand and metal to ligand charge transfer character, revealing the 
existence of low lying excited states with Ru(III)–NO(0) character.
In physiological pH, Ru-DCBPY was slowly converted to cis-[RuCl(dcbpy)2(NO2)]4− by 
nucleophilic attack of hydroxide ion (Scheme 2); kobs was 5.35 × 10−4 ± 2.47 × 10−5 s−1 at 
25.0 ± 0.1 °C (Supplementary Material: Figure 2). In pH ≤ 2.0, a precipitate starts to form, 
probably due protonation of all carboxylate substituent. In that condition, we are not being 
able to measure the pKa of bonded 4,4′-dicarboxilic acid. As judged by published pKa for 
some cis-[Ru(dcbpy-H2)2L2]n+ [64], it is reasonable to assume three equilibriums depending 
on pH for cis-[Ru(NO)Cl(dcbpy-H2)2]2+ complex (Scheme 1). In physiological pH, the best 
assumption for the molecular structure of the nitrosyl ruthenium complex discussed in this 
work is the existence of the equilibrium constant described in Eq. 3.
The electrochemistry of nitrosyl ruthenium complexes has been extensively studied in both 
aqueous and nonaqueous media [37, 39, 65, 66]. In general, these complexes undergo two 
one-electron processes between − 1.0 and 1.0 V vs. Ag/AgCl centered on the nitrogen oxide 
derivative ligand [58].
Cyclic voltammogram (CV) measurements of (Ru-DCBPY) in aqueous solution KCl 0.1 
and 0.01 M acetate buffer solution was made separately in two different scan windows to 
isolate redox events of interest. The first redox couple has E1/2 = 0.14 V (vs. Ag/AgCl) and 
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is attributed to the redox process centered on the nitrosyl group (NO+/0) when the CV was 
performed in a potential window of + 0.4 to − 0.2 V for the negative scan at the scan rate of 
100 mV s−1 at 25 °C. The ratio of the anodic (Epa) and cathodic (Epc) current peak heights 
decreases in slow scan rate consistent with a coupled chemical reaction. The results are in 
line with the loss of NO following reduction process of (Ru-DCBPY) as generally observed 
for nitrosyl ruthenium complexes [4, 5, 10–16, 22, 58, 65, 66]. A second peak attributed as 
irreversible process was observed at E1/2 = − 0.42 V (vs. Ag/AgCl), due to NO0/−, when the 
CV was performed in a potential window of + 0.4 to − 0.8 V. In aqueous solution, E1/2 for 
(Ru-DCBPY) couples shifts 0.02 V to a higher potential in comparison to cis-[Ru(NO) 
Cl(bpy)2]2+ due different σ-donor, π-acceptor character of co-ligands. It is consistent with 
the cis-[Ru(NO)L(bpy)2]3+ series where the highest π-acceptor character of L changes the 
electrochemical process centered on nitrosyl ligand to higher values [67].
Chemical reduction of (Ru-DCBPY) in 0.015 M ascorbic acid produced cis-[RuCl(dcbpy-
H)2(H2O)]− as judged by NO-sensor measurements (inset Fig. 4). Conducted 
spectroelectrochemistry at 0.1 V vs. Ag/AgCl in 0.01 M KCl pH = 3.0 controlled by the 
addition of HCl solution (Fig. 4) helped us to infer the electro-reduction process of the (Ru-
DCBPY) species (Scheme 2).
The well-established electrochemical mechanism of (Ru-DCBPY) in aqueous solution may 
help to explain some biological results related to its use as NO delivery agent. Interaction 
sites for (Ru-DCBPY) in biological medium are cell/organelles membranes, which are also 
considered potential targets of anti-cancer drugs [16, 29, 41]. Among them, mitochondrial 
plays a critical role in numerous biochemical processes, particularly oxidative 
phosphorylation, process in which ATP synthesis is driven by the transfer of electrons from 
NADH and FADH2 along the respiratory chain in the inner mitochondrial membrane 
(IMM), to molecular oxygen. This process generates electrochemical proton gradient across 
the IMM used to drive the ATP synthesis via F1F0-ATP synthase. During this process, 
mitochondrial reactive oxygen species (ROS) are produced and may elicit the mitochondrial 
permeability transition (MPT) in association with Ca2+. MPT is a cyclosporine-(CsA)-
sensitive well-documented phenomenon mediated by the opening mitochondrial transition 
pores, which is related with cellular necrosis and cellular apoptosis [68–71]. Mitochondrial 
parameters, oxidative and bioenergetics provide perspectives for anti-cancer strategies. In 
this context, we have explored the effects of NO generated from ruthenium nitrosyl (Ru-
DCBPY) on mitochondria.
First, we have determined the capability of succinate-energized isolated mitochondria induce 
NO release from (RU-DCBPY) using a selective electrode. Figure 5, in the gray area, shows 
time-course of direct determination of NO release suggesting that ruthenium complex 
underwent one-electron reduction centered on nitrogen oxide derivative ligand site, followed 
by NO release in the presence of mitochondrial NADH coenzyme. Previously, we 
demonstrated two similar mechanisms of NO release from ruthenium complexes of this 
same class, exposed to NADH [12, 16]. NADH would bind directly to metal centers of 
ruthenium and ruthenium complexes, which suggests applicability of coenzyme.
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Effects of complex (Ru-DCBPY) on mitochondrial reactive oxygen/nitrogen species (ROS/
RNS) levels and mitochondrial swelling
The production of ROS/RNS by HepG2 cells after incubation with (Ru-DCBPY) was 
examined to provide evidence on cell death mechanisms involving mitochondria. Figure 6 
shows increased ROS/RNS levels in succinate-energized mitochondria, incubated as 
indicated, through oxidation of the nonspecific probe H2DFDA [54]. The mitochondrial 
permeability transition inhibitor cyclosporine A (CsA) partially inhibited the effect of NO 
released from complex (Ru-DCBPY) at 100 μM (higher concentration).
NO released from complex (Ru-DCBPY) induced Ca2+-dependent/CsA-sensitive 
mitochondrial swelling at 10–100 μM, which attested to NO involvement in the classic 
mitochondrial permeability transition (MPT) (Fig. 7), a process usually associated with 
ROS/RNS generation [71–74]. CsA almost completely inhibited swelling induced by 
complex (Ru-DCBPY) at 50 μM. The inhibition of swelling by 2-(4-
carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (cPTIO), a NO scavenger, 
suggests that NO was the MPT inducer. We propose that in the presence of superoxide anion 
(O·−2) from mitochondria, NO generates peroxynitrite, which in turn, inhibits respiratory 
chain and elicits MPT [15, 16].
Effects of NO released from complex (Ru-DCBPY) on mitochondrial membrane potential 
and mitochondrial respiration
Respiratory control ratio (RCR: state 3/state 4 respiration rates) indicates the degree of 
mitochondrial coupling. Table 2 shows that complex (Ru-DCBPY) at 10 and 50 μM 
decreased RCR values, whilst at 100 μM it increased the values. High NO concentrations 
inhibited respiration probably because reaction between NO and superoxide generated 
peroxynitrite, an irreversible respiratory chain inhibitor [72–75]. In agreement with the RCR 
results, complex (Ru-DCBPY) decreased the mitochondrial membrane potential in a dose–
response manner (10–100 μM) (Fig. 8). Mitochondria efficiently induced NO release from 
complex (Ru-DCBPY) in a controlled way, via an oxidation–reduction mechanism. We 
propose that, once released, NO inhibited respiratory chain and raised ROS levels inducing 
MPT; ROS levels could be even increased by MPT. According to Brown and Borutaite, NO-
induced cell necrosis occurs via respiratory chain inhibition at site I and/or IV and via RNS- 
or oxidant-induced signal transduction. DNA damage may activate mitochondrial pathway 
to apoptosis. RNS-induced MPT may induce both apoptosis and necrosis. Various 
mechanisms by which NO acts to kill different types of cancer, such as breast, cervical, 
gastric, colorectal, and head and neck, have been addressed. However, local NO 
concentration is the main factor involved.
(Ru-DCBPY)–IgG conjugate
Nitrosyl ruthenium complexes may constitute useful NO delivery agents in anti-cancer 
therapy because they allow for control of the local NO concentration. We hypothesized that 
conjugating the nitrosyl ruthenium complex (Ru-DCBPY) with antibody, in basic medium, 
might improve the specificity of the complex for the target action site. Antibody–drug 
conjugates (ADCs) have been extensively studied as a promising class of anti-cancer agents. 
Cell recognition by drugs and consequent binding of the drug to target cells potentially 
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increase drug accumulation in the desired tissues and organs. In this proof-of-concept study, 
we considered a novel system involving polyclonal antibody IgG anti-VDAC, the 
mitochondrial voltage-dependent anion-selective channel, conjugated to complex (Ru-
DCBPY). The aim is targeting drugs to mitochondria, an organelle with high levels of the 
reducer agent NADH. Complex (Ru-DCBPY) covalently bound to the IgG immunoglobulin 
through a coupling reaction illustrated in Scheme 3; a previously published procedure was 
employed [56].
The resulting complex (Ru-DCBPY)–IgG conjugate was purified in a Sephadex G-25 
column. UV–Vis spectroscopy helped to identify the separated fractions containing the 
complex (Ru-DCBPY)–IgG conjugate. The eluted conjugates were analyzed by Western 
blotting. Figure 9 depicts the comparative cytotoxicity on the Hepg2 cell line induced by 
free VDAC, complex (Ru-DCBPY) and complex (Ru-DCBPY)–IgG conjugate. The 
viability of HepG2 cell decreased in the presence of selected fractions from the column 
separation, containing the conjugates (fractions 14–17) as compared to the control (cell 
culture medium only), free VDAC, cis-[RuCl2(dcbpy-H)2] and free (Ru-DCBPY). Cellular 
uptake measured for aqueous complex (Ru-DCBPY) was in the order of 10−8 mol L−1, 
which contained the (Ru-DCBPY)–IgG conjugate. Cytotoxicity was probably a 
consequence of interactions between the anti-VDAC antibody conjugate and the 
mitochondrial VDAC protein [72, 73].
In principle, the remaining complex (Ru-DCBPY) in the complex (Ru-DCBPY)–IgG 
conjugate underwent chemical reaction in the cancer cell membrane. This process could be 
attributed to the reduction of conjugated (Ru-DCBPY) or oxygen transfer reaction of cis-
[RuCl(dcbpy)2(NO2)]4− generating NO, which may have reacted with superoxide to give 
peroxynitrite, a species that inhibits the mitochondrial respiration process by several 
biochemical pathways [16]. Typically, these mitochondrial events are involved in cell death 
and can potentially kill tumor cells.
Conclusions
The use of an antibody–nitrosyl ruthenium complex conjugate was shown to be able to kill 
the HepG-2 cancer cell line. Local NO release accounted for the observed cytotoxicity, 
which could be explained by the (Ru-DCBPY) complex targeting the mitochondrial VDAC 
where it undergoes reduction and NO release. Alterations of the NAD+/NADH redox couple 
have also been described as a new mechanism for anti-cancer drug activity, and may be 
involved in the cytotoxicity of the (Ru-DCBPY)–IgG conjugate.
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Fig. 1. 
Schematic representation of the molecular structure of cis-[Ru(NO)Cl(dcbpy)2]2−
Ramos et al. Page 16
J Biol Inorg Chem. Author manuscript; available in PMC 2019 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. 
Molecular orbital diagram for species number 6
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Fig. 3. 
Experimental and (TD)DFT-computed spectra for [Ru(NO) Cl(dcbpy-H)2]. The computed 
spectrum corresponds to species number 7
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Fig. 4. 
Spectroelectrochemistry measurements of (Ru-DCBPY) (7.4 × 10−5 M) in aqueous 0.01 M 
KCl solution, pH = 3.0. Inset: Chronoamperometry with NO sensor of aqueous (Ru-
DCBPY) (7.4 × 10−5 M) containing ascorbic acid (0.015 M)
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Fig. 5. 
Release of NO from (Ru-DCBPY), evaluated by mitochondria-dependent oxy-reduction 
systems, detected directly through selective electrode. (Ru-DCBPY) (100 μM) was 
incubated with mitochondria in standard medium. The plot, representative of three 
independent experiments, shows NO release. Gray area shows time course after 
mitochondria addition
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Fig. 6. 
Time course of mitochondrial ROS generation in the presence of NO released from complex 
(Ru-DCBPY), as assessed with H2DCFDA. Mitochondria (0.5 mg protein mL−1) were 
incubated in the standard medium described in Fig. 1, at 30 °C, in the presence of 5 μM 
succinate + 2.5 μM rotenone. Plots are representative of at least three experiments with 
different mitochondrial preparations
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Fig. 7. 
Time course of mitochondrial swelling induced by NO released from complex (Ru-
DCBPY). Mitochondria (0.5 mg protein mL−1) were incubated in the standard medium 
described in Fig. 1, at 30 °C, in the presence of 5 μM succinate + 2.5 μmol L−1 rotenone. 
Data are representative of at least three experiments with different mitochondrial 
preparations
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Fig. 8. 
Time course of membrane potential induced by NO released from complex (Ru-DCBPY) in 
succinate-energized mitochondria. Mitochondria (1 mg of protein mL−1) were incubated 
with 10–100 μM of (Ru-DCBPY) in the standard medium, in the presence of 5 μM 
succinate (plus 2.5 μmol L−1 rotenone), at 30 °C. Plots are representative of at least three 
experiments with different mitochondrial preparations
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Fig. 9. 
MTT cell viability assay. Effects on HepG2 cell viability of follow treatments: control, 
DMEM cell culture medium; VDAC (IgG anti-VDAC antibody solubilized in DMEM 
medium); complex (I), ruthenium nitrosyl complex Ru-DCBPY not conjugated with IgG 
anti-VDAC antibody, e.g., Ru-DCBPY; Fractions 14, 15, 16, and 17 were from the conjugate 
purification on a Sephadex column, as described in “Materials and methods”, (Ru-DCBPY)–
IgG. The experiments were performed in triplicate, independently, and expressed as the 
mean and standard deviation
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Scheme 1. 
Effect of pH on the chemical composition of cis-[Ru(NO)Cl(dcbpy-H2)2]2+ complex
Ramos et al. Page 25
J Biol Inorg Chem. Author manuscript; available in PMC 2019 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Scheme 2. 
Control reduction potential electrolysis of (Ru-DCBPY) specie at 0.1 V vs. Ag/AgCl in pH 
3.0
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Scheme 3. 
Chemical synthesis of the NHS-ester of (Ru-DCBPY) ligation, in basic medium, with IgG 
anti-VDAC antibody (protein)
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Table 1
Structural parameters, IR frequencies and relative energies for the different cis-[Ru(NO)Cl(dcbpy)2Hn]n−2 
species computed in this computations. The labels employed to identify the protonation sites correspond to the 
ones in Fig. 1
N Species Protonation pattern dRu–N(O) (Å) dN–O (Å) Ru–N–O νNOa Fractionb
Isolated system
 0 1 – 1.771 1.192 173.2 1808 100
 1 2 a 1.790 1.194 174.3 1790 78.8
3 b 1.786 1.193 175.2 1797 2.5
4 c 1.774 1.190 175.2 1811 0.8
5 d 1.783 1.193 174.0 1795 18.0
 2 6 a–b 1.802 1.194 173.4 1785 80.1
7 a–c 1.787 1.189 175.3 1808 0.4
8 a–d 1.794 1.192 174.1 1798 1.1
9 b–c 1.783 1.188 174.6 1815 0.0
10 b–d 1.792 1.192 175.4 1797 0.5
11 c–d 1.790 1.192 175.0 1799 17.9
With explicit water molecules
 0 1 – 1.771 1.189 173.2 1819 100
 1 2 a 1.780 1.189 173.4 1814 54.0
3 b 1.777 1.188 175.0 1820 9.4
4 c 1.768 1.187 175.1 1829 4.1
5 d 1.774 1.188 173.7 1819 32.5
 2 6 a–b 1.793 1.191 175.3 1801 53.0
7 a–c 1.782 1.187 175.1 1819 4.5
8 a–d 1.786 1.189 174.1 1812 8.4
9 b–c 1.779 1.186 174.6 1826 1.5
10 b–d 1.785 1.189 175.5 1813 11.0
11 c–d 1.780 1.189 175.9 1816 21.6
aComputed for the optimized geometries in vacuo, values in cm−1
bComputed on the basis of the zero-point corrected energies arising from the PCM computations, neglecting entropic contributions
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Table 2
Effects of NO released from complex (Ru-DCBPY) on respiratory parameters of succinate-energized isolated 
rat liver mitochondria (1 mg protein mL−1) in standard medium
Mitochondrial parameters dcbpy (μM)
Control 10 50 100
V3 (ng of O atoms min−1) 231.5 ± 6.3 197.0 ± 11.3 202.2 ± 1.4 123.6 ± 7.7
V4 (ng of O atoms min−1) 31.3 ± 2.2 34.5 ± 2.1 48.3 ± 8.1 120. ± 8.3*
VCCCP 245.1 ± 7.4 189.1 ± 5.3* 250.4 ± 8.9 255.1 ± 4.6
RCR 6.4 ± 1.4 5.8 ± 1.5 4.3 ± 0.5 1.3 ± 0.9*
ADP/O 2.0 ± 0.2 1.7 ± 0.2 1.7 ± 0.3 1.3 ± 0.4*
*Values are presented as mean ± SEM (n = 3), P < 0.05 vs. control
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